What is Unique about Amicus Therapeutics?
Amicus Therapeutics is a publicly owned pharmaceutical company that is located in Cranbury in New Jersey. The company has been public from 2007 using the FOLD symbol under NASDAQ. It is distinguishable from other similar companies given that the medicine niche that they address is unique and uncommon. As a global biotechnology firm, the company utilizes modern technologies and research to develop evidence based therapies and treatments for these orphan diseases. The drugs manufactured at Amicus Therapeutics are to cater for the orphan and rare disorders. They selectively and keenly seek to address these needs as a result of the company’s desire and priority for their patients.
The chairman and chief executive officer, John Crowley asserts that their desire to ensure the achieving of the bold vision associated with addressing the devastating diseases that only the passionate and strong willed can attain. The Amicus Therapeutics team have remained in the industry because of their persistence and resilience and a commitment to see good health among the patients. The team spirit allows the company to excel they try to personalize the challenges experienced by their patients such that they work like it’s they or close friends or family who are suffering from the rare disease (https://www.crunchbase.com/organization/amicus-therapeutics). The outcome of such a team is great results and incredible improvement of health and outlook for their patients.
Products available at Amicus Therapeutics
Amicus Therapeutics lead product candidate is known as migalastat which is a customized drug which is in its final stages of development that has been manufactured for the treatment of patients with Fabry disease based on the genetic diagnosis. SD-101 is another product on the late stages of development which offers treatment for Epidermolysis Bullosa (EB). EB is a rare genetic disorder of the connective tissue. In the development of therapy, Amicus Therapeutics uses Chaperone-Advanced Replacement Therapy (CHART) platform and biology related technologies to develop treatments for Lysosomal Storage Disorders, Pompe disease, among other rare and devastating diseases. The dedication of Amicus Therapeutics ensures that there is hope for humanity, as diseases are now easily manageable (Twitter).